SIL KASALLIGI QOʻZGʻATUVCHISINING ANTIBIOTIKLARGA REZISTENTLIK XUSUSIYATI: ZAMONAVIY MOLEKULYAR-GENETIK MEXANIZMLAR VA EPIDEMIOLOGIK XUSUSIYATLARI
Keywords:
Kalit soʻzlar: Mycobacterium tuberculosis, koʻp dorilarga chidamli sil (MDR- TB), keng dorilarga chidamli sil (XDR-TB), rpoB, katG, bedaquilin, BPaLM rejimi, butun genomli sekvenirlash, antimikrob rezistentlik, Markaziy Osiyo.Abstract
ANNOTATSIYA
Maqolada sil kasalligi qoʻzgʻatuvchisi Mycobacterium tuberculosis ning
birinchi va ikkinchi qator antitubekulyoz preparatlarga rezistentligini belgilovchi
molekulyar-genetik mexanizmlar, jahon va Markaziy Osiyo mintaqasidagi
epidemiologik holat hamda yangi qisqa muddatli rejimlar (BPaL/BPaLM) ning
samaradorligi tahlil qilingan. Ishda 2010–2025-yillarda nashr etilgan 95 dan ortiq
tadqiqot natijalari sintez etilib, rpoB, katG, inhA, embB, gyrA, Rv0678 genlaridagi
nuqtaviy mutatsiyalar, efflyuks tizimi faolligi va devor tarkibidagi mikolik kislotalar
moduliyatsiyasining rezistent fenotipni shakllantirishdagi roli koʻrib chiqilgan.
Olingan natijalar shuni koʻrsatadiki, MDR/RR-TB ulushi mintaqada hamon yuqori
darajada saqlanmoqda; bedaquilinga orttirilgan rezistentlik esa yangi xavotirli
tendensiya hisoblanadi.
References
FOYDALANILGAN ADABIYOTLAR ROʻYXATI
1. World Health Organization. Global Tuberculosis Report 2024. Geneva: WHO
Press, 2024. 68 p. ISBN 978-92-4-010153-1.
2. Bayat Bodaghi A., Shariati A., Shamseddin J., et al. Mechanisms of Antibiotic
Resistance and Novel Therapeutic Approaches for Mycobacterium tuberculosis: A Narrative Review // Health Science Reports. 2025. Vol. 8, № 10. Article
71313. DOI: 10.1002/hsr2.71313.
3. Zhang S., Cheng J., Tang Y. Drug resistance mechanisms in Mycobacterium
tuberculosis infection and challenges in vaccine development // Frontiers in
Pharmacology. 2026. Vol. 17. Article 1762214. DOI:
10.3389/fphar.2026.1762214.
4. Poulton N. C., Rock J. M. Unraveling the mechanisms of intrinsic drug resistance
in Mycobacterium tuberculosis // Frontiers in Cellular and Infection Microbiology.
2022. Vol. 12. Article 997283. DOI: 10.3389/fcimb.2022.997283.
5. Jones R. M., Adams K. N., Eldesouky H. E., Sherman D. R. The evolving biology
of Mycobacterium tuberculosis drug resistance // Frontiers in Cellular and Infection
Microbiology. 2022. Vol. 12. Article 1027394. DOI:
10.3389/fcimb.2022.1027394.
6. The CRyPTIC Consortium. Genome-wide association studies of global
Mycobacterium tuberculosis resistance to 13 antimicrobials in 10,228 genomes
identify new resistance mechanisms // PLoS Biology. 2022. Vol. 20, № 8.
e3001755. DOI: 10.1371/journal.pbio.3001755.
7. Conradie F., Diacon A. H., Ngubane N., et al. Bedaquiline, pretomanid, and
linezolid for treatment of extensively drug-resistant tuberculosis (Nix-TB) // The
New England Journal of Medicine. 2020. Vol. 382, № 10. P. 893–902. DOI:
10.1056/NEJMoa1901814.
8. Merker M., Barbier M., Cox H., et al. Compensatory evolution drives multidrug-
resistant tuberculosis in Central Asia // eLife. 2018. Vol. 7. e38200. DOI:
10.7554/eLife.38200.
9. Gegia M., Saidova A., Parpieva N., et al. Trends, Characteristics and Treatment
Outcomes of Patients with Drug-Resistant Tuberculosis in Uzbekistan: 2013–2018
// International Journal of Environmental Research and Public Health. 2021. Vol.
18, № 9. Article 4775. DOI: 10.3390/ijerph18094775.
10. Nasiri M. J., Calcagno A., Hosseini S. S., et al. Mutations and insights into the
molecular mechanisms of resistance of Mycobacterium tuberculosis to first-line
anti-tuberculosis drugs // Journal of Global Antimicrobial Resistance. 2023. Vol.
32. P. 39–51. DOI: 10.1016/j.jgar.2022.12.013.
